Clinical Trials In Ontario
Discover hundreds of clinical trials in Ontario.
Search clinical trials in Ontario by city, condition or phase.
Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Head and Neck Cancer
Sponsor:
Sunnybrook Health Sciences Centre
Location:
Code:
NCT04431648
Conditions
Head and Neck Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DEFINITY
Sonalleve Focused Ultrasound Device
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT05754957
Conditions
Acute Coronary Syndrome
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Milvexian
Placebo
Feasibility of tDCS as an Adjunct to Outpatient Physiotherapy in Children With ABI
Sponsor:
Holland Bloorview Kids Rehabilitation Hospital
Location:
Code:
NCT05637957
Conditions
Acquired Brain Injury
Stroke
Traumatic Brain Injury
Hemiparesis
Eligibility Criteria
Sex: All
Age: 5 - 18
Healthy Volunteers: Not accepted
Interventions
active transcranial direct current stimulation
sham transcranial direct current stimulation
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Sponsor:
Canadian Cancer Trials Group
Location:
Code:
NCT04161248
Conditions
Lymphoma, B-Cell
Eligibility Criteria
Sex: All
Age: 16 - 65
Healthy Volunteers: Not accepted
Interventions
Venetoclax
Rituximab Injection
Rituximab SC
Gemcitabine
Dexamethasone
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03871257
Conditions
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
Eligibility Criteria
Sex: All
Age: 2 - 21
Healthy Volunteers: Not accepted
Interventions
Carboplatin
Magnetic Resonance Imaging
Quality-of-Life Assessment
Questionnaire Administration
Selumetinib Sulfate
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
Sponsor:
Ottawa Hospital Research Institute
Location:
Code:
NCT03677557
Conditions
Primary Immunodeficiency Disease
Secondary Immunodeficiency
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
16,5% Cutaquig
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
Sponsor:
GlaxoSmithKline
Location:
Code:
NCT06261957
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Salbutamol HFA-134a
Salbutamol HFA-152a
Promoting Cognitive Health in Schizophrenia
Sponsor:
Douglas Mental Health University Institute
Location:
Code:
NCT05661448
Conditions
Schizophrenia
Cognition
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cognitive remediation
MetaCognitive Training